Zeneca confident on merger
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ZENECA YESTERDAY brushed aside the possibility that its planned pounds 21bn merger with Sweden's Astra to form the third-largest drugs group in the world could be derailed by a counter-bid.
Sir David Barnes, the Zeneca chief executive, told reporters that he did not believe the merger would be disrupted by the last-ditch intervention of another bidder. Market rumours have suggested that Glaxo Wellcome and SmithKline Beecham, the two UK giants, or the Swiss group Roche could move in for Zeneca.
Sir David's comments came as Zeneca revealed a 7.5 per cent fall to pounds 817m in pre-tax profits in the nine months to the end of September.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments